P677: Azathioprine dosing and metabolite measurement in paediatric inflammatory bowel disease—does one size fit all?ECCO '18 Vienna
2018
P678: Risk of malnutrition in patients with inflammatory bowel diseases: Results from an Italian multi-centre observational cross-sectional studyECCO '18 Vienna
2018
P679: Risk factors for disease relapse after stepping down from combination to anti-TNF monotherapy in children with IBDECCO '18 Vienna
2018
P680: Machine learning (ML) in RCU-operated patients: Can we predict postoperative complications?ECCO '18 Vienna
2018
P681: Systematic review and meta-analysis of the safety and efficacy of intra-fistular injections of mesenchymal stem cells in clinical trials and observational cohort studiesECCO '18 Vienna
2018
P683: Maintenance of deep remission in patients with ulcerative colitis treated with thiopurines after withdrawal of the drug: Perspective real-life experience of a single centreECCO '18 Vienna
2018
P685: Patient’s performance and feedback by using home test faecal calprotectin as an objective reported outcomeECCO '18 Vienna
2018
P686: Endoscopic follow-up and therapeutic attitude after ileocolonic resection in a nationwide Spanish cohort of Crohn’s disease patients: PRACTICROHN studyECCO '18 Vienna
2018
P687: Female sex is associated with discontinuation of subcutaneous anti-TNF therapy for side effects in inflammatory bowel diseaseECCO '18 Vienna
2018
P688: Demographic, clinical, and therapeutic characteristics of a cohort of 238 patients with ulcerative colitis from two medical centres from UruguayECCO '18 Vienna
2018
P689: UK Asians are prescribed vedolizumab earlier in disease history than Caucasians, but respond equally well to therapyECCO '18 Vienna
2018
P690: Clinical and endoscopic outcomes of one year golimumab treatment in patients with active ulcerative colitis: A real-life observational studyECCO '18 Vienna
2018
P691: Cx601, a novel stem cell therapy for complex perianal fistulas in Crohn’s disease has rapid onset of clinical remission and low relapse rate by week 52ECCO '18 Vienna
2018
P692: Efficacy and safety of early biologic treatment of Crohn’s disease in adult and paediatric patients: A systematic reviewECCO '18 Vienna
2018
P693: Should extraintestinal manifestations (EIMs) be part of disease activity assessment in ulcerative colitis?ECCO '18 Vienna
2018
P694: Non-medical mandatory reversed and back and forth switch between infliximab and its biosimilar: Early clinical outcomesECCO '18 Vienna
2018